Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 2
1963 3
1964 1
1965 2
1966 1
1967 2
1968 4
1969 5
1970 6
1971 4
1972 10
1974 6
1975 12
1976 4
1977 16
1978 3
1979 1
1980 5
1981 6
1982 7
1983 6
1984 13
1985 15
1986 11
1987 10
1988 6
1989 9
1990 8
1991 11
1992 7
1993 7
1994 4
1995 6
1996 3
1997 1
1998 2
1999 4
2000 2
2001 1
2002 3
2003 3
2004 9
2005 12
2006 16
2007 25
2008 23
2009 21
2010 18
2011 16
2012 21
2013 24
2014 13
2015 8
2016 14
2017 20
2018 13
2019 19
2020 18
2021 17
2022 13
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

506 results

Results by year

Filters applied: . Clear all
Page 1
Mucosal penetration enhancement.
Sezaki H. Sezaki H. J Drug Target. 1995;3(3):175-7. doi: 10.3109/10611869509015941. J Drug Target. 1995. PMID: 8705248 No abstract available.
Clinicopathological assessment of steatohepatitic hepatocellular carcinoma.
Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H. Yamaoka K, et al. Among authors: sezaki h. Clin Res Hepatol Gastroenterol. 2022 Oct;46(8):101799. doi: 10.1016/j.clinre.2021.101799. Epub 2021 Sep 7. Clin Res Hepatol Gastroenterol. 2022. PMID: 34500120 Free article.
A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.
Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y. Fujiwara N, et al. Among authors: sezaki h. Med. 2021 Jul 9;2(7):836-850.e10. doi: 10.1016/j.medj.2021.03.017. Epub 2021 Apr 21. Med. 2021. PMID: 34318286 Free PMC article.
Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors.
Akuta N, Kawamura Y, Fujiyama S, Nakamichi K, Saegusa E, Ogura H, Kato M, Doi E, Inoue N, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Suzuki Y, Kumada H, Suzuki F. Akuta N, et al. Among authors: sezaki h. Hepatol Res. 2023 Jul;53(7):607-617. doi: 10.1111/hepr.13897. Epub 2023 Mar 17. Hepatol Res. 2023. PMID: 36891614
[Drug delivery systems].
Sezaki H. Sezaki H. Gan To Kagaku Ryoho. 1985 Nov;12(11):2077-82. Gan To Kagaku Ryoho. 1985. PMID: 3904633 Review. Japanese.
Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma.
Kawamura Y, Akuta N, Shindoh J, Matsumura M, Okubo S, Tominaga L, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Kawamura Y, et al. Among authors: sezaki h. Cancers (Basel). 2023 Jul 26;15(15):3789. doi: 10.3390/cancers15153789. Cancers (Basel). 2023. PMID: 37568605 Free PMC article.
[Pharmaceutics].
Sezaki H. Sezaki H. Yakushigaku Zasshi. 1996;31(1):7-11. Yakushigaku Zasshi. 1996. PMID: 11619108 Japanese. No abstract available.
506 results